Treatment of depression with onabotulinumtoxinA: A randomized, double-blind, placebo controlled trial

Journal of Psychiatric Research

Volumn 52, Issue 1, 2014, Pages 1-6

  Finzi, Eric ^a   Rosenthal, Norman E ^b,c  

^a Chevy Chase Cosmetic Center   (United States)

^b Capital Clinical Research Associates   (United States)

^c GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antidepressant; Clinical trial; Corrugator; Depression; Double blind; OnabotulinumtoxinA

Indexed keywords

BOTULINUM TOXIN A; PLACEBO; ACETYLCHOLINE RELEASE INHIBITOR;

ADULT; ANTIDEPRESSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DSM-IV; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MIDDLE AGED; MONTGOMERY ASBERG DEPRESSION RATING SCALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; REMISSION; TREATMENT RESPONSE; DEPRESSIVE DISORDER, MAJOR; NONPARAMETRIC TEST; PSYCHOLOGICAL RATING SCALE; STATISTICAL MODEL;

ACETYLCHOLINE RELEASE INHIBITORS; ADULT; BOTULINUM TOXINS, TYPE A; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PSYCHIATRIC STATUS RATING SCALES; STATISTICS, NONPARAMETRIC;

EID: 84895886129     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2013.11.006     Document Type: Article

References (45)

1. American Psychiatric Association The diagnostic and statistical manual of mental disorders, DSM IV 1994.
2. Adelmann P.K., Zajonc R.B. Facial efference and the experience of emotion. Annu Rev Psychol 1989, 40:249-280.
3. Baldessarini R.J., Marsh E. Fluoxetine and side effects. Arch Gen Psychiatry 1990, 47(2):191-192.
4. Bang H., Ni L., Davis C.E. Assessment of blinding in clinical trials. Control Clin Trials 2004, 25:143-156.
5. Beck A.T., Ward C.H., Mendelson M., Mock J., Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961, 4:561-571.
6. Beck A.T., Steer R.A., Brown G.K. Manual for the Beck Depression Inventory 1996, Psychological Corp, San Antonio, Tex. 2nd ed.
7. Beer K. Cost effectiveness of botulinum toxins for the treatment of depression: preliminary observations. JDrugs Dermatol 2010, 9:27-30.
8. Brin M.F., Boodhoo T.I., Pogoda J.M., James L.M., Demos G., Terashima Y., et al. Safety and tolerability of OBA in the treatment of facial lines: a meta-analysis of individual patient data from global clinical registration studies in 1678 participants. JAm Acad Dermatol 2009, 61:961-970.
9. Burgen A.S.V., Dickens F., Zatman L.J. The action of botulinum toxin on the neuro-muscular junction. JPhysiol 1949, 109:10-24.
10. Carney R.M., Hong B.A., O'Connell M.F., Amano H. Facial electromyography as a predictor of treatment outcome in depression. Br J Psychiatry 1981, 138:485-489.
11. Carruthers J.D., Carruthers J.A. Treatment of glabellar frown lines with C. botulinum- A exotoxin. Journal of Dermatologic Surgery & Oncology 1992, 18:17-21.
12. Clayton A., Keller A., McGarvey E.L. Burden of phase-specific sexual dysfunction with SSRIs. JAffect Disord 2006, 91(1):27-32.
13. Darwin C.R. The expression of emotion in man and animals 1872, Murray, London.
14. Ekman P. Emotions revealed: recognizing faces and feelings to improve communication 2007, Owl Books, New York.
15. Ekman P., Levenson P.W., Friesen W.V. Autonomic nervous system activity distinguishes among emotions. Science 1983, 4616:1208-1210.
16. Finzi E., Wasserman E. Treatment of depression with botulinum toxin A: a case series. Dermatol Surg 2006, 32:645-649.
17. Finzi E. The face of emotion: how Botox affects moods and relationships 2013, Palgrave-Macmillan, New York.
18. Flack W. Peripheral feedback effects of facial expressions, bodily postures, andvocal expressions on emotional feelings. Cognition and Emotion 2006, 20:177-195.
19. Greden J.F. The burden of disease for treatment-resistant depression. JClin Psychiatry 2001, 62(Suppl.16):26-31.
20. Greden J.F., Genero N., Price H.L. Agitation-increased electromyogram activity in the corrugator muscle region: a possible explanation of the "Omega sign"?. Am J Psychiatry 1985, 142:348-351.
21. Guy W. The clinical global severity and impression scales. ECDEU assessment manual for psychopharmacology 1976, 218-222. Superintendent of Documents,US Government Printing Office,US Department of Health,Education and Welfare Publication, Washington(DC), No. 76-338.
22. Heckmann M., Teichmann B., Schröder U., Sprengelmeyer R., Ceballos-Baumann A.O. Pharmacologic denervation of frown muscles enhances baseline expression of happiness and decreases baseline expression of anger, sadness, and fear. JAm Acad Dermatol 2003, 49:213-216.
23. Hennenlotter A., Dresel C., Castrop F., Ceballos-Baumann A.O., Wohlschläger A.M., Haslinger B. The link between facial feedback and neural activity within central circuitries of emotion-new insights from botulinum toxin-induced denervation of frown muscles. Cereb Cortex 2009, 19:537-542.
24. Honeck P., Weiss C., Sterry W., Rzany B. Reproducibility of a four- point clinical severity score for glabellar frown lines. Br J Dermatol 2003, 10:149-306. Gladys study group.
25. James W. The principles of psychology 1890, Holt, New York.
26. Larsen R.J., Kasimatis M., Frey K. Facilitating the furrowed brow: an unobtrusive test of the facial feedback hypothesis applied to unpleasant affect. Cognition and Emotion 1992, 6:321-338.
27. Lewis M.B. Exploring the positive and negative implications of facial feedback. Emotion 2012, 12:852-859.
28. Mathers C.D., Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006, 3(11):e442.
29. Montgomery S.A., Asberg M. Anew depression scale designed to be sensitive to change. Br J Psychiatry 1979, 134:382-389.
30. Neal D.T., Chartrand T.L. Embodied emotion perception: amplifying and dampening facial feedback modulates emotion perception accuracy. Social Psychological and Personality Science 2011, 2(6):673-678.
31. Niedenthal P.M., Winkielman P., Mondillon L., Vermeulen N. Embodiment of emotion concepts. JPers Soc Psychol 2009, 96,(6):1120-1136.
32. Nierenberg A.A., DeCecco L.M. Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: a focus on treatment-resistant depression. JClin Psychiatry 2001, 62(Suppl.16):5-9.
33. Perlis R.H., Ostacher M., Fava M., Nierenberg A.A., Sachs G.S., Rosenbaum J.F. Assuring that double-blind is blind. Am J Psychiatry 2010, 167:250-252.
34. Pollack M.H., Rosenbaum J.F. Management of antidepressant-induced side effects: a practical guide for the clinician. JClin Psychiatry 1987, 48(1):3-8.
35. Rabkin J.G., Markowitz J.S., Stewart J., McGrath P., Harrison W., Quitkin F.M., et al. How blind is blind? assessment of patient and doctor medication guesses in a placebo-controlled trial of imipramine and phenelzine. Psychiatry Res 1986, 19:75-86.
36. Remick R.A., Froese C., Keller F.D. Common side effects associated with monoamine oxidase inhibitors. Progress in Neuropsychopharmacology & Biological Psychiatry 1989, 13(3-4):497-504.
37. Rutherford B.R., Sneed J.R., Roose S.P. Does study design influence outcome? The effects of placebo control and treatment duration in antidepressant trials. Psychother Psychosom 2009, 78:172-181.
38. Schwartz G.E., Fair P.L., Salt P., Mandel M.R., Klerman G.L. Facial muscle patterning to affective imagery in depressed and nondepressed subjects. Science 1976, 192:489-491.
39. Serna M.C., Cruz I., Real J., Gascó E., Galván L. Duration and adherence of antidepressant treatment (2003-2007) based on prescription database. Eur Psychiatry 2010, 25:206-213.
40. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. JClin Psychiatry 1998, 59(Suppl.20):22-33. quiz 34-57.
41. Soussignan R. Duchenne smile, emotional experience, and autonomic reactivity: a test of the facial feedback hypothesis. Emotion 2002, 2:52-74.
42. Strack F., Martin L.L., Stepper S. Inhibiting and facilitating conditions of the human smile: a nonobtrusive test of the facial feedback hypothesis. JPers Soc Psychol 1988, 54(5):768-777.
43. Teasdale J., Bancroft J. Manipulation of thought content as a determinant of mood and corrugator EMG activity in depressed patients. JAbnorm Psychol 1977, 86:235-241.
44. Ustün T.B., Ayuso-Mateos J.L., Chatterji S., Mathers C., Murray C.J. Global burden of depressive disorders in the year 2000. Br J Psychiatry 2004, 184:386-392.
45. Wollmer M.A., de Boer C., Kalak N., Beck J., Götz T., Schmidt T., et al. Facing depression with botulinum toxin: a randomized controlled trial. JPsychiatr Res 2012, 46(5):574-581.